This is the content of the pop-over!

Lightning Deal Alert – 12% Off Ends at Midnight!

Strike while the savings are hot! Use promo code FlashSale at checkout for 12% off any Exam Edge test or bundle. Hurry—the clock is ticking!

ABIM Rheumatology Practice Tests & Exam Prep Questions - Additional Information


ABIM Rheumatology practice tests

Pass the ABIM Rheumatology exam with confidence

Realistic practice tests, detailed explanations, and instant access—built to help you feel ready on test day.

Trusted by serious test takers
Real exam simulationInstant, 24/7 accessDetailed explanations
Instant access  •  No software required  •  Study at your pace
Featured on
ABIM Rheumatology Practice Test Realistic practice • Detailed explanations • Instant access
Choose your plan

Practice smarter. Walk in prepared.

Every plan includes realistic exam simulation, detailed explanations, and immediate online access.



ABIM Rheumatology - Additional Information

ABIM Rheumatology Study Guide | ExamEdge
Study Guide

ABIM Rheumatology Study Guide

Prepare for the ABIM Rheumatology with clear domain sections, detailed topic coverage, study guidance, and practice-focused resources.

test, 200 total questions, 480 minutes, passing score 75 | 51 practice tests available

What is the ABIM Rheumatology?

The ABIM Rheumatology study guide is designed to help candidates understand the main content areas, review the most important topics, and prepare in a more focused way.

This page organizes the available topic information for the ABIM test into clear study sections so candidates can prioritize review and practice more effectively.

How this study guide is organized

Use this study guide to review the content areas, understand how the exam is structured, and identify where to spend the most study time. Candidates usually get the best results by reviewing the highest-priority domains first, then reinforcing weaker areas with practice tests.

ABIM domain sections

The sections below show the available topic coverage for this exam. Where topic percentages are available, they can help you prioritize your study time.

Basic and Clinical Sciences

Weight: 7%
  • Know the inflammatory vs noninflammatory synovial fluid cutoffs (e.g., >2,000 WBC/µL suggests inflammation; >50,000 raises septic arthritis concern)—red flag: treating “flares” without aspirating a hot monoarthritis.
  • Interpret serologies in pretest probability: RF and anti-CCP can be positive in other conditions, and low-titer ANA is common in healthy people—common trap: diagnosing SLE solely from ANA without clinical criteria.
  • Use ESR/CRP appropriately: CRP rises and falls faster than ESR and is less affected by age/anemia—priority rule: don’t use ESR/CRP to “rule out” inflammatory disease when symptoms are classic.
  • Apply imaging strengths: ultrasound/MRI detect synovitis and early erosions before plain radiographs—common trap: calling early inflammatory arthritis “normal” based on normal X-rays alone.
  • Recognize drug toxicities and monitoring basics (e.g., methotrexate hepatotoxicity/cytopenias; hydroxychloroquine retinal toxicity with risk rising at >5 mg/kg/day actual body weight)—contraindication cue: avoid methotrexate in pregnancy and significant liver disease.
  • Differentiate true myopathy/neuropathy from pain syndromes using patterns (proximal weakness, CK, EMG, reflexes)—red flag: objective weakness with elevated CK warrants evaluation for inflammatory myositis or statin-associated necrotizing myopathy.

Crystal-induced Arthropathies

Weight: 5%
  • Acute monoarthritis: perform arthrocentesis before antibiotics or intraarticular steroids; red flag — treat any hot swollen joint as septic arthritis until proven otherwise.
  • Synovial fluid microscopy: monosodium urate crystals are needle-shaped and negatively birefringent, whereas CPPD are rhomboid and positively birefringent; common trap — crystals do not exclude concomitant infection.
  • Urate-lowering therapy (ULT): do not start or stop allopurinol/febuxostat solely because of an acute flare; priority rule — if initiating ULT, co-prescribe flare prophylaxis (colchicine/NSAID/low-dose prednisone) for 3–6 months.
  • Colchicine use: adjust for renal impairment and avoid strong CYP3A4/P-gp inhibitors (e.g., clarithromycin) due to myotoxicity risk; contraindication — severe renal/hepatic disease with interacting drugs.
  • CPPD clues: consider hemochromatosis, hyperparathyroidism, hypomagnesemia, and hypothyroidism in recurrent or early-onset CPPD; practical cue — check magnesium and iron studies when presentation is atypical.
  • Biologic and imaging pitfalls: ultrasound “double contour” supports gout and chondrocalcinosis supports CPPD, but neither is definitive; common trap — overcalling gout based on serum urate (may be normal during a flare).

Infections and Related Arthritides

Weight: 6%
  • Assume septic arthritis until proven otherwise in any acute hot monoarthritis; red flag: fever or immunosuppression plus inability to bear weight warrants urgent arthrocentesis before antibiotics if feasible.
  • Synovial fluid WBC >50,000/µL with neutrophil predominance is strongly suggestive but not definitive; common trap: ruling out infection because crystals are present—crystal arthritis and septic arthritis can coexist.
  • Gonococcal arthritis often presents with migratory polyarthralgia/tenosynovitis and few organisms on Gram stain; priority rule: obtain NAAT from genital/pharyngeal/rectal sites even if joint cultures are negative.
  • Always consider prosthetic joint infection in painful arthroplasty (early <3 months, delayed 3–24 months, late >24 months); red flag: new pain with elevated ESR/CRP should prompt aspiration before starting antibiotics.
  • Lyme arthritis classically causes intermittent or persistent large-joint (knee) effusion with relatively mild pain; common trap: treating with steroids intra-articularly before appropriate antibiotics and excluding infection.
  • Reactive arthritis typically follows GU/GI infection and is sterile on culture; contraindication: avoid empiric immunosuppression until septic arthritis and disseminated gonococcal infection have been reasonably excluded.

Metabolic Bone Disease

Weight: 5.5%
  • Suspect osteoporosis after a low-trauma fracture (hip, vertebra, proximal humerus, pelvis) regardless of BMD, and treat without waiting for DXA if a fragility fracture is confirmed—common trap is dismissing a “fall from standing” as high-energy.
  • Before starting antiresorptives, correct vitamin D and hypocalcemia and check renal function; red flag: give IV bisphosphonate or denosumab in untreated hypocalcemia and precipitate symptomatic hypocalcemia.
  • Differentiate osteomalacia from osteoporosis: low 25(OH)D with elevated alkaline phosphatase (often with hypophosphatemia) points to osteomalacia; common trap is treating “osteoporosis” with bisphosphonate when the real issue is mineralization failure.
  • Evaluate hypercalcemia by PTH first: elevated/inappropriately normal PTH suggests primary hyperparathyroidism (think nephrolithiasis, cortical bone loss), whereas suppressed PTH should prompt malignancy/vitamin D excess workup—red flag is ordering extensive malignancy testing before checking PTH.
  • For suspected Paget disease (bone pain, elevated ALP with normal transaminases, focal lesions), confirm with imaging and treat with bisphosphonate if symptomatic or at high-risk sites (skull, spine, weight-bearing bones); trap: attributing isolated ALP elevation to liver disease without checking GGT or bone-specific ALP.
  • In chronic glucocorticoid use (e.g., =2.5 mg prednisone equivalent for =3 months), prioritize fracture prevention early (calcium/vitamin D, fall-risk mitigation, and pharmacotherapy based on risk)—common ABIM pitfall is waiting for a repeat DXA after prolonged steroid exposure.

Osteoarthritis and Related Disorders

Weight: 5%
  • Diagnose OA clinically: activity-related pain with brief morning stiffness (<30 minutes) and bony enlargement (Heberden/Bouchard nodes); red flag is prolonged morning stiffness or synovitis suggesting inflammatory arthritis.
  • Get weight-bearing knee radiographs when diagnosis is uncertain or symptoms are disproportionate; common trap is treating x-ray OA findings when pain is minimal (radiographic severity correlates poorly with symptoms).
  • Prioritize nonpharmacologic therapy first-line (exercise/physical therapy, weight loss, braces/cane for knee/hip); ABIM-style pitfall is skipping weight loss in knee OA because it has a dose-dependent benefit.
  • Use topical NSAIDs before oral NSAIDs for knee/hand OA, especially in older adults; contraindication cue is oral NSAIDs in CKD, high GI bleed risk, or uncontrolled hypertension without gastroprotection.
  • Intra-articular corticosteroid injections can give short-term relief for knee OA flares; red flag is injecting a hot, swollen joint without excluding septic arthritis (aspirate if concern).
  • Differentiate related disorders: thumb CMC OA causes pinch-grip pain, while erosive hand OA shows central erosions (“gull-wing”) and can mimic RA; trap is ordering RF/anti-CCP for typical OA without inflammatory features.

Rheumatoid Arthritis

Weight: 13%
  • Classify RA with the 2010 ACR/EULAR criteria (joints + serology + acute-phase reactants + duration) and remember the ABIM trap: a single swollen large joint with negative serologies is often not RA—rule out crystal or infection first.
  • Start a treat-to-target strategy with frequent reassessment (about every 1–3 months when active) and early DMARD use; red flag: delaying methotrexate or using chronic prednisone as “bridge” beyond a short course increases infection/osteoporosis risk.
  • Methotrexate is first-line unless contraindicated—avoid in pregnancy and significant liver disease/alcohol misuse, and give folic acid; practical cue: check CBC/AST/ALT/Cr regularly and think “new dyspnea/cough” = possible MTX pneumonitis.
  • Before biologic/targeted synthetic DMARDs, screen for TB and hepatitis B and update vaccines; common trap: starting anti-TNF in an undiagnosed latent TB patient or giving live vaccines while on biologics/JAK inhibitors.
  • Recognize extra-articular disease (nodules, ILD, scleritis, vasculitis) and cervical spine involvement; red flag: neurologic symptoms or pre-op intubation planning warrants C1–C2 instability evaluation.
  • Manage comorbid risk aggressively—cardiovascular risk is elevated and glucocorticoids worsen it; practical cue: chronic NSAID/steroid use without GI and bone protection (PPI when high-risk, calcium/vitamin D and osteoporosis prevention) is a frequent board-style pitfall.

Spondyloarthritis

Weight: 6.5%
  • Suspect axial spondyloarthritis with chronic back pain >3 months starting before age 45 plus inflammatory features (morning stiffness, improvement with exercise, nocturnal pain)—red flag: pain worse with rest and better with activity.
  • Order MRI of the sacroiliac joints when plain films are normal but suspicion is high; common trap: relying on HLA-B27 alone (it supports but does not confirm the diagnosis).
  • First-line treatment is NSAIDs at adequate dose/duration before escalating; priority rule: reassess response after a true NSAID trial rather than jumping directly to biologics.
  • For persistent active axial disease, use a TNF inhibitor or IL-17 inhibitor; contraindication cue: avoid TNF inhibitors in demyelinating disease or severe heart failure.
  • Differentiate axial vs peripheral patterns and associated entities (psoriatic arthritis, IBD-associated arthritis, reactive arthritis); common trap: missing uveitis—acute painful red eye needs urgent ophthalmology.
  • Screen for infection risk prior to biologics (TB, hepatitis B) and update nonlive vaccines; red flag: do not give live vaccines while on biologic therapy or high-dose immunosuppression.

Other Rheumatic and Connective Tissue Disorders (ORCT)

Weight: 16.5%
  • Systemic sclerosis: new dyspnea or declining DLCO is a red flag for pulmonary arterial hypertension or ILD—screen at least annually with echocardiogram and PFTs, and treat Raynaud’s/ulcers with vasodilators (avoid high-dose steroids due to scleroderma renal crisis risk).
  • Idiopathic inflammatory myopathies: proximal weakness with elevated CK warrants checking for interstitial lung disease and malignancy risk (highest in dermatomyositis)—don’t mistake normal CK for “no myositis” when weakness is prominent or on steroids.
  • Sjögren syndrome: persistent parotid enlargement, palpable purpura, low C4, or cryoglobulinemia are lymphoma red flags—objective dryness testing (Schirmer/ocular staining) and anti-Ro/La help avoid overcalling sicca from meds/aging.
  • Mixed connective tissue disease/overlap: high-titer anti-U1 RNP with Raynaud’s and swollen hands suggests overlap—trap is anchoring on one label and missing organ threats (PAH/ILD) that drive prognosis and monitoring.
  • Relapsing polychondritis: auricular chondritis sparing the lobule and hoarseness/stridor are airway red flags—avoid assuming “otitis externa” and consider urgent airway evaluation when respiratory symptoms occur.
  • Antiphospholipid syndrome: unprovoked thrombosis or pregnancy morbidity plus persistent antibodies (repeat =12 weeks apart) supports diagnosis—common trap is ordering/acting on transient low-titer anticardiolipin during acute infection.

Lupus Erythematosus

Weight: 9%
  • Suspect lupus nephritis with new proteinuria or hematuria—don’t rely on creatinine alone; persistent proteinuria (=0.5 g/day or UPCR =0.5) is a biopsy trigger.
  • When disease activity is in question, prioritize complements and anti-dsDNA over ANA titers—a falling C3/C4 with rising dsDNA is a common flare pattern (trap: ANA stays positive regardless of activity).
  • Always keep hydroxychloroquine as baseline therapy unless contraindicated—red flag is missed retinal screening (baseline, then typically annually after 5 years or earlier if high-risk).
  • Differentiate antiphospholipid syndrome from lupus flare in thrombosis or pregnancy loss—confirm with persistent lupus anticoagulant/anticardiolipin/anti-ß2GPI positivity =12 weeks apart (trap: treating acute thrombosis with DOACs in high-risk triple-positive APS).
  • Neuropsychiatric symptoms need exclusion of infection and steroid psychosis first—priority rule: immunosuppression for NPSLE only after ruling out mimics (red flag: fever, neck stiffness, neutrophilic CSF).
  • Vaccination and infection prevention are testable safety points—contraindication: avoid live vaccines on significant immunosuppression and screen for hepatitis B/TB before high-grade agents like cyclophosphamide or rituximab.

Nonarticular and Regional Musculoskeletal Disorders

Weight: 7%
  • Distinguish inflammatory vs mechanical pain: morning stiffness >60 minutes, improvement with activity, and night pain are red flags for inflammatory disease rather than tendinopathy.
  • Evaluate suspected septic bursitis (olecranon/prepatellar) with aspiration before antibiotics when feasible; red flag is overlying cellulitis or fever—treat as infection until proven otherwise.
  • Carpal tunnel syndrome: nocturnal paresthesias in thumb/index/middle with thenar weakness warrants urgent evaluation; common trap is missing cervical radiculopathy when symptoms extend proximal to the elbow.
  • Rotator cuff disease vs adhesive capsulitis: preserved passive ROM suggests cuff pathology, whereas loss of both active and passive ROM suggests frozen shoulder; contraindication is steroid injection without ruling out infection or fracture.
  • Low back pain with radicular features: progressive motor deficit, saddle anesthesia, or new bladder/bowel dysfunction is a cauda equina red flag requiring emergent imaging and referral.
  • Fibromyalgia: widespread pain with nonrestorative sleep and normal inflammatory markers should prompt nonpharmacologic first-line therapy (exercise/CBT); common trap is escalating opioids, which generally worsen function and hyperalgesia.

Nonrheumatic Systemic Disorders

Weight: 9%
  • Differentiate inflammatory myopathy from endocrinopathy/toxic myopathy: CK elevation plus proximal weakness supports myositis, while statin toxic myopathy can persist with anti-HMGCR antibodies—red flag is dysphagia or rapidly progressive weakness prompting urgent evaluation.
  • Screen systemic endocrine causes of musculoskeletal pain: hypothyroidism can mimic inflammatory arthritis with effusions/carpal tunnel, and hyperparathyroidism causes bone pain with subperiosteal resorption—trap is treating as RA without checking TSH and calcium/PTH.
  • Recognize paraneoplastic rheumatic syndromes: new-onset polymyalgia-like symptoms, hypertrophic osteoarthropathy, or refractory seronegative arthritis warrants malignancy workup—red flag is constitutional symptoms or atypical age/course for classic rheumatic disease.
  • Assess hepatic/renal drivers of joint symptoms: hepatitis C can cause intermittent oligoarthritis/cryoglobulinemia and ESRD can cause dialysis-related amyloid arthropathy—priority rule is to test for HCV and review renal replacement history before escalating immunosuppression.
  • Identify hematologic/systemic infiltrative mimics: amyloidosis can cause shoulder pad sign, carpal tunnel, and nonerosive arthropathy—red flag is nephrotic-range proteinuria or unexplained cardiomyopathy alongside musculoskeletal complaints.
  • Handle diabetes-related musculoskeletal disorders: limited joint mobility, adhesive capsulitis, and diabetic cheiroarthropathy are common—trap is attributing hand stiffness to inflammatory synovitis when exam shows tight skin/positive prayer sign without true joint swelling.

Vasculitides

Weight: 8.5%
  • Use vessel size and key clinical syndromes to narrow the diagnosis (e.g., jaw claudication/vision symptoms ? giant cell arteritis) and treat suspected GCA with high-dose glucocorticoids immediately—do not wait for biopsy or imaging.
  • In ANCA-associated vasculitis, distinguish pulmonary–renal syndrome (hemoptysis + rising creatinine/hematuria) and prioritize urgent induction (glucocorticoids + rituximab or cyclophosphamide)—a common trap is missing diffuse alveolar hemorrhage when hemoglobin is falling with a normal chest exam.
  • Interpret ANCA thoughtfully: PR3-ANCA suggests GPA and MPO-ANCA suggests MPA/EGPA, but ANCA positivity is not diagnostic by itself—red flag for mimics includes cocaine/levamisole exposure or drug-induced ANCA (e.g., hydralazine) with atypical features.
  • Suspect polyarteritis nodosa when there is mononeuritis multiplex, livedo reticularis, abdominal pain, and renal infarcts with hypertension but no glomerulonephritis—priority rule is to screen for hepatitis B because treatment and prognosis change.
  • In IgA vasculitis, look for palpable purpura with arthralgia and abdominal pain, and monitor for nephritis with urinalysis and blood pressure—common trap is underestimating renal risk in adults despite skin-limited presentation.
  • For cryoglobulinemic vasculitis, link palpable purpura, neuropathy, low complement (especially low C4), and glomerulonephritis to chronic hepatitis C or lymphoproliferative disease—contraindication/pitfall is giving immunosuppression without addressing the underlying driver (e.g., antivirals for HCV).

Miscellaneous Topics

Weight: 2%
  • Pre-immunosuppression screening: check TB (IGRA/PPD), hepatitis B (HBsAg, anti-HBc, anti-HBs) and consider Strongyloides in exposure history; red flag is starting high-dose steroids/biologic with unexplained eosinophilia or untreated HBV risk.
  • Vaccines in rheumatology: give inactivated vaccines anytime, but avoid live vaccines on significant immunosuppression (e.g., prednisone =20 mg/day for =14 days or on biologics); common trap is forgetting to vaccinate (zoster/pneumococcal) before initiating a JAK inhibitor or anti-TNF.
  • Glucocorticoid stewardship: use the lowest dose/shortest duration and plan a taper; priority rule is bone protection if prednisone =2.5 mg/day for =3 months (calcium/vitamin D and consider antiresorptive therapy by fracture risk).
  • DMARD/biologic safety monitoring: methotrexate requires folic acid and LFT/CBC surveillance (avoid in pregnancy and significant liver disease); red flag is new dyspnea/cough on MTX suggesting pneumonitis.
  • Perioperative management: generally hold biologics for one dosing interval before elective surgery and restart after adequate wound healing/no infection; common trap is stopping conventional DMARDs unnecessarily and triggering a flare.
  • Hyperuricemia and urate-lowering therapy basics: do not treat asymptomatic hyperuricemia routinely; red flag is starting allopurinol without flare prophylaxis (colchicine/NSAID/low-dose steroid) and provoking an acute attack.

Key topics tested on the ABIM

Based on the available topic records, these are some of the main areas to review:

  • Basic and Clinical Sciences
  • Crystal-induced Arthropathies
  • Infections and Related Arthritides
  • Metabolic Bone Disease
  • Osteoarthritis and Related Disorders
  • Rheumatoid Arthritis
  • Spondyloarthritis
  • Other Rheumatic and Connective Tissue Disorders (ORCT)
  • Lupus Erythematosus
  • Nonarticular and Regional Musculoskeletal Disorders

14-day study schedule (90 minutes a day, using all 3 test modes)

Modes referenced below: Mode 1 = Tutor/Study (untimed + explanations), Mode 2 = Timed, Mode 3 = Review (missed questions + weak areas).

Day Goal What to do in 90 minutes
Day 1 Baseline diagnostic
  • 30 min - Mode 2 (Timed): Take a short diagnostic set to establish your baseline.
  • 30 min - Mode 3 (Review): Review every missed or guessed question and write down weak domains.
  • 30 min - Mode 1 (Tutor/Study): Rework the weakest questions using explanations.
Day 2 Weakest domain focus
  • 35 min - Mode 1 (Tutor/Study): Study your weakest domain section from the guide.
  • 25 min - Mode 2 (Timed): Do a short timed set only on that topic.
  • 30 min - Mode 3 (Review): Review misses and create a redo list.
Day 3 Second weak domain
  • 35 min - Mode 1 (Tutor/Study): Study your next weakest domain.
  • 25 min - Mode 2 (Timed): Timed practice on that domain.
  • 30 min - Mode 3 (Review): Review explanations and redo missed items.
Day 4 Mixed-topic reinforcement
  • 30 min - Mode 1 (Tutor/Study): Review notes from Days 1 to 3.
  • 30 min - Mode 2 (Timed): Mixed-topic timed set.
  • 30 min - Mode 3 (Review): Review patterns in your mistakes.
Day 5 Third and fourth domains
  • 35 min - Mode 1 (Tutor/Study): Cover two additional topic sections.
  • 25 min - Mode 2 (Timed): Short timed quiz on those sections.
  • 30 min - Mode 3 (Review): Focus on missed concepts and confusing answer choices.
Day 6 Speed and accuracy
  • 25 min - Mode 1 (Tutor/Study): Quick review of weak notes.
  • 35 min - Mode 2 (Timed): Faster timed set with mixed content.
  • 30 min - Mode 3 (Review): Review misses and any slow questions.
Day 7 Halfway progress check
  • 45 min - Mode 2 (Timed): Take a longer timed set or half-length exam.
  • 25 min - Mode 3 (Review): Review all misses.
  • 20 min - Mode 1 (Tutor/Study): Reinforce the top 2 weak domains.
Day 8 Weak-area reset
  • 40 min - Mode 1 (Tutor/Study): Deep review of the worst-performing domain from Day 7.
  • 20 min - Mode 2 (Timed): Short focused timed set on that domain.
  • 30 min - Mode 3 (Review): Redo missed questions without looking at the explanation first.
Day 9 High-weight content review
  • 35 min - Mode 1 (Tutor/Study): Review the highest-weight topics shown in the guide.
  • 25 min - Mode 2 (Timed): Timed practice on those high-priority areas.
  • 30 min - Mode 3 (Review): Review every error and note recurring issues.
Day 10 Mixed endurance practice
  • 20 min - Mode 1 (Tutor/Study): Quick concept review.
  • 40 min - Mode 2 (Timed): Mixed timed set across all covered domains.
  • 30 min - Mode 3 (Review): Review misses and weak answer patterns.
Day 11 Full-content reinforcement
  • 30 min - Mode 1 (Tutor/Study): Review all topic summaries and weak notes.
  • 30 min - Mode 2 (Timed): Mixed set emphasizing previously missed areas.
  • 30 min - Mode 3 (Review): Redo missed questions until you can get them right.
Day 12 Full practice simulation
  • 50 min - Mode 2 (Timed): Take the longest available practice set or near full exam.
  • 25 min - Mode 3 (Review): Review misses and slow questions.
  • 15 min - Mode 1 (Tutor/Study): Reinforce the top weak points.
Day 13 Final weak-spot cleanup
  • 40 min - Mode 1 (Tutor/Study): Focus only on your weakest 2 to 3 domains.
  • 20 min - Mode 2 (Timed): Quick timed drill on those same areas.
  • 30 min - Mode 3 (Review): Build a final last-day review list.
Day 14 Final confidence check
  • 35 min - Mode 2 (Timed): Final mixed-topic timed set.
  • 25 min - Mode 3 (Review): Review misses quickly and focus on patterns.
  • 30 min - Mode 1 (Tutor/Study): Light reinforcement on your last weak areas and confidence review.

How to study for the ABIM

  • Review the domain sections first and focus on the highest-priority topics.
  • Use the topic descriptions to understand what each section is really testing.
  • Spend extra time on areas where your knowledge is weakest.
  • Use practice tests to improve pacing, accuracy, and confidence.
  • Repeat difficult topics over multiple study sessions instead of cramming them all at once.

Frequently asked questions

What does the ABIM Rheumatology cover?

The ABIM Rheumatology covers the topic areas shown in the study guide below. Review each domain section and topic description to understand what knowledge areas to study.

What is the format of the ABIM test?

The exact format details available for this exam include 200 total questions and 480 minutes for the full test.

What is the passing score for the ABIM?

The passing score listed for this exam is 75. Candidates should still verify the latest scoring requirements before taking the real exam.

How should I study for the ABIM?

Start with the domain sections, focus first on weaker areas and higher-priority topics, then use repeated review and practice tests to improve pacing and confidence.

Why use practice tests for ABIM?

Practice tests help you identify weak areas, improve familiarity with the structure of the exam, and build confidence through repeated review.

Prepare for the ABIM

Use the study guide, review the official exam details, and strengthen your preparation with practice-focused resources.

Official Exam Info